You are here

In vitro Models Suitable for High-throughput Screening of Drug Toxicities in Human Tissues

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-10-P-0037
Agency Tracking Number: C101-103-0113
Amount: $69,869.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD10-103
Solicitation Number: 2010.1
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-05-17
Award End Date (Contract End Date): 2010-11-16
Small Business Information
401 W. Morgan Road,
Ann Arbor, MI 48108
United States
DUNS: 622797327
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Kelechi Anyaogu
 Senior Scientist
 (734) 945-8131
Business Contact
 Elvira Stesikova
Title: Project Manager
Phone: (734) 945-8131
Research Institution

The drug R&D cycle is long and very expensive. In many ways, this status quo can no longer be sustained. One of the reasons for such great cost is that the vast majority of drug candidates are screened out at the stages of animal and human trials. More efficient methods of testing of drugs at the stage of ex-vivo studies, which are substantially less expensive than animal and human testing cycles, will lead to improvement of the success rate of preclinical trials, acceleration of drug discovery, reduction of the cost of pharmaceutical development, and better drugs. In this Phase I SBIR project involving a start-up company Nico Technology Corporation (NTCorp) and the University of Michigan, we propose the development of a new type of 3D scaffold that can (1) rectify the problems of existing 3D matrixes and (2) provide the pharmaceutical industry the possibility to develop convenient and reliable protocols for drug assessment in organ replicas, and in particular ex-vivo bone marrow construct.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government